Our Pricing

Understanding the Clinical Difference Between Ozempic and Wegovy

The difference between Ozempic and Wegovy UK patients often ask about centres on licensing, dosing, and intended use — despite both containing the same active ingredient, semaglutide. At Cured Pharmacy, our UK-registered clinical team helps you understand which semaglutide treatment is appropriate for your health goals, with transparent pricing and expert guidance throughout your assessment.

What Is the Main Difference Between Ozempic and Wegovy?

Both Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1. However, they are licensed by the MHRA for different clinical indications and formulated at different maximum doses [1]. Ozempic is licensed specifically for type 2 diabetes management at doses up to 1mg weekly, whilst Wegovy is licensed exclusively for chronic weight management at doses up to 2.4mg weekly [2].

This distinction matters clinically. Wegovy's higher dose was studied extensively in the STEP trial programme, which demonstrated average weight reductions of 15% over 68 weeks in adults with obesity [2]. Ozempic's lower maximum dose, whilst effective for glycaemic control and producing some weight loss as a secondary effect, was not studied or approved at the therapeutic levels needed for primary obesity treatment.

In the UK, prescribing a medication outside its licensed indication — known as off-label use — requires careful clinical justification. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures all prescriptions at Cured Pharmacy align with MHRA licensing and current clinical guidelines, protecting both patient safety and treatment efficacy.

Ozempic vs Wegovy Dosing and Administration

Ozempic uses a different escalation pattern designed for diabetes management. Treatment typically begins at 0.25mg weekly for four weeks, increasing to 0.5mg weekly as the standard maintenance dose [1]. Some patients may be escalated to 1mg weekly if additional glycaemic control is needed, but this remains well below Wegovy's therapeutic weight loss dose.

The difference between Ozempic and Wegovy dosing schedules reflects their distinct therapeutic goals. Wegovy's higher maximum dose was specifically studied for its effect on body weight reduction, appetite suppression, and metabolic health markers in people with obesity, whilst Ozempic's dosing optimises HbA1c reduction and fasting glucose control in type 2 diabetes [2][3].

Wegovy Dose Escalation Schedule

Wegovy follows a structured 16-week titration schedule, starting at 0.25mg weekly and gradually increasing to the maintenance dose of 2.4mg weekly [3]. This gradual escalation minimises gastrointestinal side effects such as nausea and vomiting, which are the most commonly reported adverse events in clinical trials. Each pre-filled pen delivers a single weekly subcutaneous injection, typically administered in the abdomen, thigh, or upper arm.

Which Treatment Is Right for Your Health Goals?

If your primary concern is type 2 diabetes management rather than weight loss, Ozempic may be the more appropriate choice, subject to prescriber assessment. However, if you are seeking a licensed weight management treatment and meet the clinical criteria, Wegovy offers the evidence-based dosing studied specifically for chronic obesity treatment.

At Cured Pharmacy, we only prescribe medications within their MHRA-licensed indications. This means Wegovy is available for eligible patients seeking weight management, whilst Ozempic would only be considered for those with a confirmed type 2 diabetes diagnosis. Our clinical team reviews every assessment individually, ensuring you receive the treatment that aligns with both regulatory guidance and your health needs.

Eligibility Criteria for Wegovy in the UK

Wegovy is licensed for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea [3]. Your UK prescriber will assess your medical history, current medications, and weight management goals during your free online consultation to determine suitability.

Wegovy and Ozempic Clinical Trial Data Compared

The STEP 1 trial, which studied Wegovy at its licensed 2.4mg dose, enrolled 1,961 adults with obesity or overweight with comorbidities. Participants achieved an average weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [2]. Importantly, 86.4% of participants on Wegovy achieved at least 5% weight loss, and 69.1% achieved at least 10% weight loss — thresholds associated with meaningful metabolic health improvements.

Ozempic's pivotal trials, including SUSTAIN 1-5, focused on glycaemic outcomes in type 2 diabetes. Whilst participants did experience weight loss averaging 4-6kg over 30-56 weeks, this was a secondary endpoint rather than the primary study objective [1]. The trials were not designed to evaluate semaglutide's efficacy at the higher doses used in Wegovy, nor were participants selected based on obesity criteria alone.

This difference in trial design and population is critical when comparing Ozempic and Wegovy. Wegovy's evidence base specifically supports its use as a chronic weight management treatment in people with obesity, whilst Ozempic's evidence supports glycaemic control in type 2 diabetes with weight loss as a beneficial secondary effect [2][3].

Side Effects and Safety Considerations

Serious but rare side effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly when used alongside other glucose-lowering medications). Both Ozempic and Wegovy carry a black box warning in some jurisdictions regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans [1][3]. As a precaution, neither medication should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Your UK prescriber will review your complete medical history during your online assessment to identify any contraindications. At Cured Pharmacy, we provide ongoing clinical support throughout your treatment, and you can contact our team on (+44) 116 4646009 if you experience any concerning symptoms whilst taking Wegovy or any other prescribed medication.

Managing Common Side Effects

Both treatments share a similar side effect profile due to their identical active ingredient. The most frequently reported adverse events include nausea, diarrhoea, vomiting, constipation, and abdominal pain, particularly during dose escalation [2][3]. These gastrointestinal effects typically diminish over time as your body adjusts to the medication. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated can help minimise discomfort.

Getting Prescribed Wegovy at Cured Pharmacy

We guarantee the lowest prices in the UK on genuine, licensed medicines. Every Wegovy pen supplied by Cured Pharmacy is sourced through regulated UK pharmaceutical wholesalers, ensuring full traceability and authenticity. Unlike some online providers, we never supply unlicensed or compounded versions of semaglutide — you receive only MHRA-approved treatments.

Understanding the difference between Ozempic and Wegovy helps you make an informed choice about your health. If you meet the eligibility criteria for weight management treatment and are ready to begin your journey, start your free online assessment today. Our clinical team is here to support you every step of the way, with expert guidance grounded in evidence-based medicine and UK regulatory standards.

Transparent Pricing and Next Steps

Wegovy is available at Cured Pharmacy with upfront pricing displayed before you begin your consultation. Our clinical assessment takes under three minutes to complete and is reviewed by a UK-registered prescriber who will determine your suitability for treatment. If approved, your medication is dispensed by our GPhC-registered pharmacy (9012511) and delivered in 100% discreet packaging to your chosen address.

Scientific References

1. Sorli, C., Harashima, S. I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology, 5(4), 251–260. https://doi.org/10.1016/S2213-8587(17)30013-X
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/13799
4. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., Lingvay, I., & STEP 2 Study Group. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.